134 related articles for article (PubMed ID: 21079232)
1. Extended-duration venous thromboembolism prophylaxis for medical patients.
Dentali F; Gianni M; Squizzato A
Ann Intern Med; 2010 Nov; 153(10):688; author reply 689-90. PubMed ID: 21079232
[No Abstract] [Full Text] [Related]
2. Extended-duration venous thromboembolism prophylaxis for medical patients.
Carson MP; Kuo YH
Ann Intern Med; 2010 Nov; 153(10):689; author reply 689-90. PubMed ID: 21079233
[No Abstract] [Full Text] [Related]
3. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
[TBL] [Abstract][Full Text] [Related]
4. Extended-duration venous thromboembolism prophylaxis for medical patients.
Nieto JA; Valle R; Lopez-Saez JB
Ann Intern Med; 2010 Nov; 153(10):688-9; author reply 689-90. PubMed ID: 21079231
[No Abstract] [Full Text] [Related]
5. Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?
Ann Intern Med; 2010 Jul; 153(1):I-50. PubMed ID: 20621897
[No Abstract] [Full Text] [Related]
6. Differences in the safety profiles of two low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2008 Jun; 99(6):989-90. PubMed ID: 18521496
[No Abstract] [Full Text] [Related]
7. Does ambulation modify venous thromboembolism risk in acutely ill medical patients?
Amin AN; Girard F; Samama MM
Thromb Haemost; 2010 Nov; 104(5):955-61. PubMed ID: 20838741
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate for prevention of venous thromboembolism.
Eikelboom JE; Weitz JI
Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
[No Abstract] [Full Text] [Related]
9. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
Chi G; Yee MK; Amin AN; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
Circulation; 2018 Jan; 137(1):91-94. PubMed ID: 29279341
[No Abstract] [Full Text] [Related]
10. Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional study.
Haas S; Hohmann V; Bramlage P
Clin Appl Thromb Hemost; 2012 Jun; 18(3):265-71. PubMed ID: 22084412
[TBL] [Abstract][Full Text] [Related]
11. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
12. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
[TBL] [Abstract][Full Text] [Related]
14. Current primary care practice in the diagnosis and management of patients with suspected venous thromboembolism and prescription of initiation dose of enoxaparin.
Verhamme P; Motte S; Claes N; Verhaeghe R; Hermans C
Int Angiol; 2010 Feb; 29(1):58-63. PubMed ID: 20224534
[TBL] [Abstract][Full Text] [Related]
15. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
16. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
17. Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
Kistler U; Kramers-de Quervain I; Munzinger U; Kucher N
Thromb Haemost; 2008 Jun; 99(6):1049-52. PubMed ID: 18521507
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Deitelzweig SB; Becker R; Lin J; Benner J
Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
[TBL] [Abstract][Full Text] [Related]
19. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
[TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis Following Robot-assisted Radical Cystectomy: A Retrospective Feasibility Study at a Single Academic Medical Center.
Ortiz RM; Golijanin B; O'Rourke TK; Sobel DW; Pillsbury L; T Tucci C; Caffery P; Golijanin D
Urology; 2021 Oct; 156():154-162. PubMed ID: 34171347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
